Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6896441 | 0.78 | ALDH1A1 (0.33) | IDO1TDO2IRAK4KDM4EALDH1A1 | |
| SCHEMBL6895652 | 0.77 | CYP11B2 (0.39) | OPRL1OGFRL1PRKACAGSK3BRPS6KB1 | |
| SCHEMBL17678111 | 0.77 | KDM4E (0.52) | IDO1TDO2PRKACAGSK3BRPS6KB1 | |
| SCHEMBL10012295 | 0.76 | IRAK4 (0.31) | IDO1TDO2IRAK4 | |
| SCHEMBL10298620 | 0.76 | PRKACA (0.38) | OPRL1OGFRL1PRKACAGSK3BRPS6KB1 | |
| SCHEMBL6893935 | 0.74 | OGFRL1 (0.46) | OPRL1OGFRL1 | |
| SCHEMBL6897419 | 0.74 | MAPT (0.42) | IDO1TDO2IRAK4KDM4EALDH1A1 | |
| SCHEMBL6895697 | 0.74 | MAPT (0.42) | IDO1TDO2IRAK4KDM4EALDH1A1 | |
| SCHEMBL6895712 | 0.73 | MAPT (0.39) | IDO1TDO2IRAK4KDM4EALDH1A1 | |
| SCHEMBL10011272 | 0.73 | MAPT (0.44) | IDO1TDO2IRAK4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
| WO-2011031816-A2 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2011-03-17 | — | — | US | disclosed |
| WO-2011031818-A2 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065694-A1 | Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof | HRH3, HRH4, HRH2 | IDO1 284/4885TDO2 1174/4885OPRL1 106/4885 |
| US-20120172350-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | IDO1 284/4885TDO2 1174/4885OPRL1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.